InsiderTrades.com logo
An Unusual Way to Invest in Gold
From Edge On The Street   |   Ad
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
See why this overlooked gold play

1AI Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Algorae Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Algorae Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Algorae Pharmaceuticals Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 10/18/2023 12:02 PM ET

This chart shows the closing price history over time for 1AI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

Algorae Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/9/2023Bradley LathamInsiderIssued20,000,000A$0.01A$260,000.00
10/10/2023David HainsworthInsiderIssued40,000,000A$0.01A$560,000.00
See Full Table
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

SEC Filings (Institutional Ownership Changes) for Algorae Pharmaceuticals (ASX:1AI)

Algorae Pharmaceuticals Limited, a biotechnology company, focuses on developing solutions for Parkinson's disease in Australia. It is developing NTCELL, an alginate coated capsule to target the treatment of Parkinson's disease; and AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient treatment for dementia, including Alzheimer's disease. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. The company was founded in 1987 and is based in Melbourne, Australia.
Read More on Algorae Pharmaceuticals

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

4.29%

Beta

0.86

Who are the company insiders with the largest holdings of Algorae Pharmaceuticals?

Algorae Pharmaceuticals' top insider shareholders include:
  1. Bradley Latham (Insider)
  2. David Hainsworth (Insider)
Learn More about top insider investors at Algorae Pharmaceuticals.
An Unusual Way to Invest in Gold
From Edge On The Street   |   Ad
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
See why this overlooked gold play